News | January 31, 2014

PICSO Impulse System Four Month Follow-Up Shows Infarct Size-Reduction

Miracor Medical PICSO Impulse System Clinical Trial Cath Lab

Coronary sinus pressure increase during two cycles of PICSO (clinical data from the Prepare PICSO study).


January 31, 2014 — Miracor Medical Systems completed four months’ follow-up of patients enrolled in the “Prepare RAMSES” clinical trial of PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) System. PICSO is designed to improve myocardial perfusion following primary PCI (Percutaneous Coronary Intervention, or angioplasty). Interim data from early results indicate a strong trend towards a larger reduction in infarct for patients receiving the PICSO therapy in complement with primary PCI. A total of 30 patients have successfully enrolled in the clinical trial, with no device-related adverse events. 
 
The study is underway in several European centers with Principal Investigator Jan J. Piek, M.D., Ph.D., professor of interventional cardiology and director of the Heart Centre, Academic Medical Centre, University of Amsterdam. Miracor Medical is expanding PICSO’s CE marking throughout Europe. 
 
The Miracor PICSO Impulse System is designed to treat acute heart attack STEMI (ST-segment elevation myocardial infarction) patients in complement to coronary angioplasty. 
 
For more information: www.miracormedical.com

Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now